DACH2 Goat anti-Human, Mouse, Polyclonal, R&D Systems™
Goat Polyclonal Antibody
Manufacturer: R&D Systems AF5230
DACH2 (Dachshund 2) is a 65kDa (predicted) member of the DACH family of transcription factors. It is expressed in the dermomyotome and Mullerian duct, and promotes Mullerian duct formation and myogenin gene suppression. Human DACH2 is 599 amino acids (aa) in length and contains a DD1 domain in the N-terminus (aa 66-162) that mediates DNA binding, and a C-terminal, coiled-coil DD2 domain (aa 452-543) that interacts with EYA proteins. Multiple splice variants of DACH2 are known. There is an alternate start site at Met220 that may be accompanied by both a deletion of aa 259-311 and a three aa substitution for aa 585-599. In addition, there is a deletion of aa 163-175 that may be accompanied by an Ala substitution for aa 584-599. Finally, there is a 41 aa substitution for aa 1-175. Over aa 419-583, human DACH2 is 93% aa identical to mouse DACH2.
|Western Blot 1 ug/mL, Immunohistochemistry 5-15 ug/mL|
|Dach2, dachshund homolog 2, dachshund homolog 2 (Drosophila), FLJ31391, MGC138545|
|Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 degreesC as supplied. 1 month, 2 to 8 degreesC under sterile conditions after reconstitution. 6 months, -20 to -70 degreesC under sterile conditions after reconstitution.|
|Detects human and mouse DACH2 in Western blots.|
|Western Blot, Immunohistochemistry|
|Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 μm filtered solution in PBS. with No Preservative|
|E. coli-derived recombinant human DACH2 Gln419-Gln583 Accession # Q96NX9|
|Reconstitute at 0.2 mg/mL in sterile PBS.|
We continue to work to improve your shopping experience and your feedback regarding this content is very important to us. Please use the form below to provide feedback related to the content on this product.
Your feedback has been submitted. Fisher Scientific is always working to improve our content for you. We appreciate your feedback.Ok